Search results
Results from the WOW.Com Content Network
Bromazolam N-glucuronide, phenyl-hydroxy bromazolam glucuronide, α-hydroxy bromazolam glucuronide, and 4-hydroxy bromazolam glucuronide, were detected as phase II metabolites. Bromazolam N-glucuronidation was found to be catalysed by UGT1A4 and UGT2B10. The formation of α-hydroxy bromazolam glucuronide was catalysed by UGT2B4.
Rilmazafone [1] (リスミー, Rhythmy, previously known as 450191-S) is a water-soluble prodrug developed in Japan. [2] Inside the human body, rilmazafone is converted into several benzodiazepine metabolites that have sedative and hypnotic effects.
4-Hydroxycoumarins are a class of vitamin K antagonist (VKA) anticoagulant drug molecules. Chemically, they are derived from coumarin by adding a hydroxy group at the 4 position to obtain 4-hydroxycoumarin , then adding a large aromatic substituent at the 3-position (the ring-carbon between the hydroxyl and the carbonyl).
Due to conflicting findings in studies regarding benzodiazepines and increased risks of death including from cancer, further research in long-term use of benzodiazepines and mortality risk has been recommended; most of the available research has been conducted in prescribed users, even less is known about illicit misusers.
An assortment of several designer drugs. Designer drugs are structural or functional analogues of controlled substances that are designed to mimic the pharmacological effects of the parent drug while avoiding detection or classification as illegal.
Some breast cancer patients, particularly those with high-risk features such as a large number of involved lymph nodes, aggressive tumor biology, or those who do not respond adequately to standard adjuvant therapy, may be considered for HDC. However, the role of HDC in breast cancer is more controversial and is generally reserved for the ...
Nitrazolam is a triazolobenzodiazepine (TBZD) , which are benzodiazepine (BZD) derivatives, [1] that has been sold online as a designer drug. [2] [3]It is closely related to clonazolam or flunitrazolam, only differing by the removal of a chlorine or fluorine group respectively at the benzene ring.
The Brazilian Controlled Drugs and Substances Act (Portuguese: Regulamento Técnico sobre substâncias e medicamentos sujeitos a controle especial), officially Portaria nº 344/1998, [1] is Brazil's federal drug control statute, issued by the Ministry of Health through its National Health Surveillance Agency (Anvisa).